Larger studies with detailed data are needed for a comprehensive evaluation of the post-therapy imaging to assess the efficacy of 177Lu-PSMA therapy and optimize an individualized treatment for prostate cancer patients. This evidence concerns the gene FOLH1 and Familial prostate cancer.